DekaBank Deutsche Girozentrale’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$225M Hold
506,457
0.38% 62
2026
Q1
$230M Hold
506,457
0.38% 62
2025
Q4
$220M Hold
506,457
0.38% 54
2025
Q3
$200M Hold
506,457
0.34% 66
2025
Q2
$223M Buy
506,457
+15,328
+3% +$7.06M 0.4% 60
2025
Q1
$239M Sell
491,129
-15,328
-3% -$7.14M 0.47% 46
2024
Q4
$205M Hold
506,457
0.38% 59
2024
Q3
$233M Buy
506,457
+4,948
+1% +$2.38M 0.43% 52
2024
Q2
$237M Buy
501,509
+10,380
+2% +$4.51M 0.43% 51
2024
Q1
$204M Sell
491,129
-12,849
-3% -$5.43M 0.38% 61
2023
Q4
$206M Buy
503,978
+33,920
+7% +$12.5M 0.42% 50
2023
Q3
$166M Buy
470,058
+4,020
+0.9% +$1.41M 0.38% 55
2023
Q2
$163M Buy
466,038
+13,635
+3% +$4.59M 0.37% 60
2023
Q1
$141M Buy
452,403
+18,758
+4% +$5.63M 0.35% 64
2022
Q4
$125M Buy
433,645
+10,927
+3% +$3.33M 0.33% 76
2022
Q3
$123M Sell
422,718
-49,786
-11% -$14.3M 0.36% 62
2022
Q2
$131M Sell
472,504
-7,636
-2% -$2.04M 0.38% 57
2022
Q1
$124M Buy
480,140
+141,885
+42% +$33.7M 0.3% 79
2021
Q4
$76M Sell
338,255
-6,454
-2% -$1.26M 0.18% 126
2021
Q3
$63M Buy
344,709
+8,784
+3% +$1.72M 0.18% 139
2021
Q2
$66.1M Buy
335,925
+38,249
+13% +$8M 0.19% 135
2021
Q1
$63.6M Buy
297,676
+63,181
+27% +$13.9M 0.21% 123
2020
Q4
$54.7M Sell
234,495
-20,913
-8% -$4.8M 0.21% 119
2020
Q3
$68.3M Buy
255,408
+193,226
+311% +$53.3M 0.3% 81
2020
Q2
$17.7M Buy
62,182
+3,733
+6% +$1.01M 0.11% 141
2020
Q1
$13.7M Sell
58,449
-2,895
-5% -$664K 0.1% 144
2019
Q4
$13.5M Sell
61,344
-171,690
-74% -$34.7M 0.08% 184
2019
Q3
$39M Sell
233,034
-141,130
-38% -$25M 0.24% 95
2019
Q2
$67M Buy
374,164
+267,507
+251% +$46.8M 0.34% 76
2019
Q1
$20M Buy
106,657
+3,474
+3% +$642K 0.12% 192
2018
Q4
$16.9M Sell
103,183
-3,474
-3% -$602K 0.11% 191
2018
Q3
$20M Sell
106,657
-30,777
-22% -$5.48M 0.12% 193
2018
Q2
$20.7M Sell
137,434
-39,965
-23% -$6.2M 0.13% 183
2018
Q1
$28.5M Buy
177,399
+24,037
+16% +$3.93M 0.2% 134
2017
Q4
$23.3M Hold
153,362
0.18% 137
2017
Q3
$23.3M Sell
153,362
-23,072
-13% -$3.47M 0.18% 137
2017
Q2
$22.6M Buy
176,434
+5,253
+3% +$632K 0.18% 136
2017
Q1
$18.5M Buy
171,181
+1,006
+0.6% +$88.6K 0.17% 129
2016
Q4
$12.7M Sell
170,175
-13,396
-7% -$1.09M 0.14% 164
2016
Q3
$15.6M Sell
183,571
-67,830
-27% -$6.41M 0.17% 138
2016
Q2
$21.4M Buy
251,401
+15,692
+7% +$1.36M 0.24% 98
2016
Q1
$18.5M Buy
235,709
+43,292
+22% +$3.92M 0.22% 105
2015
Q4
$24.6M Sell
192,417
-39,960
-17% -$4.82M 0.28% 80
2015
Q3
$23.7M Buy
232,377
+51,146
+28% +$6.57M 0.29% 73
2015
Q2
$22.5M Buy
181,231
+7,542
+4% +$950K 0.27% 72
2015
Q1
$20.8M Buy
173,689
+7,000
+4% +$839K 0.26% 83
2014
Q4
$19.9M Sell
166,689
-7,046
-4% -$794K 0.25% 91
2014
Q3
$19.7M Sell
173,735
-45,355
-21% -$4.32M 0.27% 84
2014
Q2
$20.5M Buy
219,090
+4,650
+2% +$326K 0.31% 75
2014
Q1
$14.6M Buy
214,440
+34,230
+19% +$2.71M 0.23% 96
2013
Q4
$13.3M Buy
180,210
+24,266
+16% +$1.69M 0.22% 93
2013
Q3
$11.7M Buy
155,944
+4,297
+3% +$342K 0.21% 96
2013
Q2
$12.2M Buy
+151,647
New +$11.2M 0.24% 87

Other funds holding VRTX

DekaBank Deutsche Girozentrale's VRTX Position: Q2 2026 in Review

DekaBank Deutsche Girozentrale held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 506,457 shares worth $225M. The position accounts for 0.38% of the portfolio, ranked #62.

DekaBank Deutsche Girozentrale first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $239M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • DekaBank Deutsche Girozentrale held 506,457 shares of Vertex Pharmaceuticals worth $225M as of Q2 2026.
  • DekaBank Deutsche Girozentrale left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.38% of DekaBank Deutsche Girozentrale's portfolio in Q2 2026, its #62 holding.
  • DekaBank Deutsche Girozentrale first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • DekaBank Deutsche Girozentrale's Vertex Pharmaceuticals position peaked at $239M in Q1 2025.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2026, filed 5 Aug 2026.